erk-mapk-signaling-neurodegeneration

Overview

The ERK/MAPK signaling pathway (Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase) represents one of the most critical intracellular signal transduction cascades in eukaryotic cells, playing a fundamental role in regulating cell proliferation, differentiation, survival, apoptosis, and synaptic plasticity 1. In the central nervous system, ERK/MAPK signaling coordinates responses to neurotrophic factors, neurotransmitters, and cellular stress, making it a pivotal pathway in neurodegenerative disease pathogenesis 2. The pathway’s central position in cellular decision-making between survival and death makes it a key therapeutic target, though its pleiotropic functions create significant challenges for intervention. ^{1CitationPMID 12420226Open reference}

The MAPK/ERK cascade consists of a three-tiered kinase phosphorylation cascade: Ras activates Raf (MAPKKK), which phosphorylates and activates MEK1/2 (MAPKK), which in turn phosphorylates and activates ERK1/2 (MAPK). Once activated, ERK1/2 translocates to the nucleus where it phosphorylates various transcription factors, regulating gene expression programs essential for neuronal survival and function 3. This sequential phosphorylation cascade provides multiple points of regulation and potential therapeutic intervention. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}

ERK/MAPK Signaling in Alzheimer’s disease

amyloid-beta-Induced ERK Activation

In Alzheimer’s disease (AD), the ERK/MAPK pathway exhibits complex, context-dependent alterations that contribute to both protective and pathogenic responses. amyloid-beta (Aβ) oligomers, the primary neurotoxic species in AD, activate ERK1/2 signaling through multiple mechanisms involving receptor-mediated signaling and cellular stress responses 4. Early-stage Aβ exposure triggers transient ERK1/2 phosphorylation, which initially may serve a neuroprotective function by activating adaptive stress responses and upregulating antioxidant defenses 5. This biphasic response reflects the pathway’s dual nature in cellular homeostasis. ^{3CitationPMID 21993227Open reference}

However, chronic Aβ exposure leads to dysregulated ERK1/2 activation that contributes to synaptic dysfunction and neuronal loss. Studies demonstrate that Aβ-induced ERK1/2 activation drives the phosphorylation of downstream targets including the transcription factor CREB (cAMP Response Element-Binding protein), which normally supports synaptic plasticity and memory formation 6. The perturbation of CREB signaling through aberrant ERK1/2 activation represents a key mechanism linking Aβ pathology to cognitive decline in AD 7. ^{4CitationPMID 23422068Open reference}

The mechanisms by which Aβ activates ERK1/2 include activation of NMDA receptors, AMPA receptors, and various tyrosine kinase receptors. Calcium influx through these channels activates Ras-Raf-MEK-ERK signaling through calcium-dependent pathways. Additionally, Aβ can directly bind to p75 neurotrophin receptors, triggering downstream ERK activation in a manner that promotes pro-death signaling rather than survival 8. ^{5CitationPMID 21331656Open reference}

Tau Pathology and ERK Signaling

The relationship between tau pathology and ERK1/2 signaling creates a vicious cycle in AD progression. Hyperphosphorylated tau protein, which forms neurofibrillary tangles, activates GSK-3β and CDK5, which in turn can either stimulate or inhibit ERK1/2 signaling depending on cellular context 9. ERK1/2 can phosphorylate tau at multiple sites including Thr181, Ser202, and Thr205, potentially accelerating tau pathology in a feed-forward mechanism 10. ^{6CitationPMID 23422672Open reference}

Post-mortem studies of AD brain tissue reveal increased ERK1/2 phosphorylation in neurons bearing neurofibrillary tangles, suggesting ongoing ERK activation in affected brain regions 11. The spatial correspondence between ERK1/2 activation and tau pathology supports the hypothesis that dysregulated ERK signaling contributes to tau-mediated neurodegeneration 12. This correlation is particularly prominent in the hippocampus and entorhinal cortex, brain regions critical for memory function. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}

The interplay between ERK1/2 and tau involves multiple kinases and phosphatases that determine net phosphorylation status. Mitogen-activated protein kinase phosphatases (MKPs) such as DUSP1 and DUSP6 provide negative feedback by dephosphorylating ERK1/2. In AD, the expression and activity of these phosphatases is often dysregulated, contributing to sustained ERK1/2 activation 13. ^{8ERK regulates mitochondrial fission protein Drp1PMID 25458867Open reference}

Synaptic Plasticity Impairment

ERK1/2 signaling plays a critical role in synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), processes underlying learning and memory 14. In AD, Aβ-induced ERK1/2 dysregulation impairs LTP while facilitating LTD, shifting the balance toward synaptic depression 15. This shift represents a fundamental mechanism of memory impairment in AD. ^{9CitationPMID 26046799Open reference}

The mechanism involves ERK1/2-dependent regulation of AMPA receptor trafficking and localization at synaptic membranes. Aβ-mediated ERK1/2 activation leads to decreased surface expression of AMPA receptors, reducing synaptic strength 16. Additionally, ERK1/2 regulates the expression and function of NMDA receptors, further disrupting synaptic transmission 17. ^{10PGC-1α and mitochondrial biogenesisPMID 25500548Open reference}

Beyond receptor trafficking, ERK1/2 controls the synthesis of synaptic proteins through regulation of translation factors. Phosphorylation of eIF4E and p70S6K by ERK1/2 promotes the translation of proteins required for synaptic plasticity. Disruption of this regulatory mechanism contributes to the synaptic protein loss observed in AD brain 18. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}0

ERK/MAPK Signaling in Parkinson’s Disease

Dopaminergic Neuron Vulnerability

In Parkinson’s Disease (PD), ERK1/2 signaling in dopaminergic neurons of the substantia nigra pars compacta exhibits striking biphasic behavior. Acute dopaminergic neuron injury triggers a protective ERK1/2 activation response that promotes cell survival through phosphorylation of pro-survival targets including Bcl-2 family proteins 19. However, this protective response becomes inadequate as disease progresses, and chronic ERK1/2 activation contributes to inflammatory responses that exacerbate neurodegeneration 20.

The MEK/ERK pathway interacts with alpha-synuclein pathology through multiple mechanisms. alpha-synuclein aggregation activates ERK1/2, which in turn promotes additional alpha-synuclein phosphorylation at Ser129, facilitating its aggregation into toxic oligomers and fibrils 21. This positive feedback loop accelerates Lewy body formation and dopaminergic neuron loss 22. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}2

The selective vulnerability of dopaminergic neurons to ERK1/2 dysregulation relates to their unique metabolic demands and calcium handling. Dopaminergic neurons exhibit autonomous pacemaking that generates cytoplasmic calcium oscillations, which can activate calmodulin-dependent pathways leading to ERK1/2 activation. This baseline calcium-dependent ERK1/2 activity, while normally protective, becomes dysregulated in the presence of cellular stress 23. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}3

mitochondrial dysfunction and ERK Signaling

mitochondrial dysfunction represents a central feature of PD pathogenesis, and ERK1/2 signaling participates in both mitochondrial quality control and dysfunction. Parkin and PINK1, proteins mutated in familial PD, regulate mitochondrial autophagy (mitophagy) through mechanisms involving ERK1/2 activation 24. Loss-of-function mutations in these genes impair mitophagy, leading to accumulation of dysfunctional mitochondria and increased oxidative stress 25. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}4

ERK1/2 also regulates mitochondrial fission through phosphorylation of Drp1 (Dynamin-related protein 1), influencing mitochondrial dynamics in dopaminergic neurons 26. In PD models, excessive ERK1/2-driven Drp1 phosphorylation promotes mitochondrial fragmentation and neuronal death 27. This fission-promoting activity represents a key mechanism linking ERK1/2 activation to mitochondrial dysfunction in PD. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}5

The regulation of mitochondrial biogenesis by ERK1/2 involves the PGC-1α transcription coactivator, which is phosphorylated and activated by ERK1/2. While acute activation supports mitochondrial health, chronic ERK1/2 activation can lead to exhaustion of mitochondrial reserve capacity 28. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}6

^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}7(/mechanisms/neuroinflammation) and Microglial ERK1/2

Microglial activation in PD involves robust ERK1/2 signaling that drives pro-inflammatory cytokine production. Environmental toxins implicated in PD pathogenesis, including rotenone and MPTP, activate microglial ERK1/2, leading to increased expression of TNF-α, IL-1β, and IL-6 29. This neuroinflammatory response contributes to the progressive loss of dopaminergic neurons 30. ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}8

Inhibition of microglial ERK1/2 activation reduces ^{2Spatial relationship between tau pathology and ERK activationPMID 16549424Open reference}9(/mechanisms/neuroinflammation) and provides neuroprotection in PD animal models 31. However, the dual role of ERK1/2 in both promoting inflammation and supporting neuronal survival makes targeting this pathway therapeutically challenging 32. The timing and cell-type specificity of ERK1/2 inhibition are critical considerations. ^{3CitationPMID 21993227Open reference}0

The complement system, which is activated in PD, interacts with ERK1/2 signaling in microglia. C1q and other complement proteins can activate ERK1/2, leading to enhanced phagocytic activity and cytokine production. This interaction provides a link between protein aggregation and ^{3CitationPMID 21993227Open reference}1(/mechanisms/neuroinflammation) in PD pathogenesis 33. ^{3CitationPMID 21993227Open reference}2

ERK/MAPK Signaling in ALS

Motor Neuron Vulnerability

In amyotrophic lateral sclerosis (ALS), ERK1/2 signaling exhibits complex alterations in motor neurons that influence disease progression. Both sporadic and familial forms of ALS demonstrate dysregulated ERK1/2 activity, with specific patterns depending on disease stage and cell type 34. Activated ERK1/2 is observed in spinal motor neurons of ALS patients, particularly in those with SOD1 mutations 35. ^{3CitationPMID 21993227Open reference}3

The TDP-43 proteinopathy characteristic of most ALS cases involves ERK1/2-dependent mechanisms. TDP-43 aggregation activates ERK1/2 signaling, which contributes to stress granule formation and further aggregation in a pathogenic cycle 36. Additionally, ERK1/2 activation promotes the phosphorylation and aggregation of TDP-43 itself 37. ^{3CitationPMID 21993227Open reference}4

Motor neurons exhibit high baseline metabolic activity and calcium handling requirements that make them particularly vulnerable to ERK1/2 dysregulation. The size and length of motor neuron axons create unique logistical challenges for protein transport and mitochondrial distribution that are affected by ERK1/2-dependent mechanisms 38. ^{3CitationPMID 21993227Open reference}5

Astrocyte-Mediated Toxicity

ERK1/2 signaling in astrocytes plays a crucial role in the non-cell-autonomous toxicity observed in ALS. Mutant SOD1 expression in astrocytes activates ERK1/2, leading to increased secretion of pro-inflammatory factors and excitotoxic molecules that harm motor neurons 39. This astrocyte-mediated toxicity is a key contributor to the progressive nature of motor neuron degeneration 40. ^{3CitationPMID 21993227Open reference}6

Targeting astrocyte ERK1/2 signaling represents a potential therapeutic strategy. Inhibition of ERK1/2 in astrocytes reduces the release of toxic factors and provides partial neuroprotection in co-culture models 41. However, complete inhibition of ERK1/2 may be detrimental given its essential roles in cellular function 42. ^{3CitationPMID 21993227Open reference}7

astrocytes in ALS show increased expression of ERK1/2-dependent inflammatory mediators including COX-2, iNOS, and various cytokines. This reactive phenotype is induced by mutant SOD1 through ERK1/2-dependent mechanisms, creating a neurotoxic microenvironment 43. ^{3CitationPMID 21993227Open reference}8

^{3CitationPMID 21993227Open reference}9(/mechanisms/neuroinflammation) in ALS

Microglial ERK1/2 activation in ALS drives chronic ^{4CitationPMID 23422068Open reference}0(/mechanisms/neuroinflammation) that accelerates disease progression. The timing of ERK1/2 activation in microglia correlates with disease progression, with early activation potentially serving a protective function and later activation contributing to neurodegeneration 44. The dual role of ERK1/2 in ^{4CitationPMID 23422068Open reference}1(/mechanisms/neuroinflammation) makes timing a critical consideration for therapeutic targeting 45. ^{4CitationPMID 23422068Open reference}2

The progression of ALS involves a shift from neuroprotective to neurotoxic microglial phenotypes. ERK1/2 signaling regulates this phenotypic transition, with chronic activation promoting the neurotoxic phenotype. Biomarkers of microglial ERK1/2 activation may serve as indicators of disease stage and progression 46. ^{4CitationPMID 23422068Open reference}3

Therapeutic Implications

MEK Inhibitors in Neurodegeneration

MEK inhibitors represent the primary pharmacological approach to targeting the ERK/MAPK pathway in neurodegenerative diseases. However, the pleiotropic functions of this pathway create significant challenges for therapeutic intervention 47. In AD models, MEK inhibitors show neuroprotective effects by reducing Aβ-induced toxicity and improving synaptic function 48. However, chronic MEK inhibition produces adverse effects including skin toxicity and gastrointestinal disturbances 49. ^{4CitationPMID 23422068Open reference}4

In PD models, MEK inhibitors provide neuroprotection in toxin-induced dopaminergic neuron loss, primarily through reduction of ^{4CitationPMID 23422068Open reference}5(/mechanisms/neuroinflammation) 50. Clinical trials of MEK inhibitors in PD have been limited by safety concerns, though novel formulations may enable better CNS penetration 51. The challenge of achieving adequate brain penetration while maintaining safety remains a significant hurdle. ^{4CitationPMID 23422068Open reference}6

The pharmacokinetic properties of MEK inhibitors, including half-life and distribution, affect their efficacy in neurodegenerative disease models. Extended-release formulations and prodrug strategies are being explored to improve CNS exposure 52. ^{4CitationPMID 23422068Open reference}7

Targeting Downstream Effectors

Given the challenges of direct MEK inhibition, targeting downstream effectors of ERK1/2 offers an alternative approach. Inhibition of ERK1/2-dependent transcription factors or kinases may provide similar benefits with improved safety profiles 53. For example, targeting RSK (Ribosomal S6 Kinase), a downstream kinase activated by ERK1/2, may preserve some neuroprotective signaling while blocking pathogenic effects 54. ^{4CitationPMID 23422068Open reference}8

Transcription factors including Elk-1, c-Fos, and CREB represent additional therapeutic targets downstream of ERK1/2. Selective modulation of these factors may allow for more precise intervention in disease-specific pathways 55. ^{4CitationPMID 23422068Open reference}9

Combination Therapies

The complexity of ERK/MAPK signaling in neurodegeneration suggests that combination therapies targeting multiple nodes of the pathway may be more effective than single-target approaches 56. Preclinical studies demonstrate synergistic benefits when MEK inhibitors are combined with agents targeting other pathways including mTOR, GSK-3β, or ^{5CitationPMID 21331656Open reference}0(/mechanisms/neuroinflammation) 57. Such combination approaches may enable lower doses of individual compounds, reducing toxicity while maintaining efficacy 58. ^{5CitationPMID 21331656Open reference}1

Rational drug combinations must consider the network biology of signaling pathways. Computational models help predict synergistic combinations and potential adverse interactions 59. ^{5CitationPMID 21331656Open reference}2

Biomarkers and Diagnostics

ERK Phosphorylation as a Biomarker

ERK1/2 phosphorylation status in peripheral blood mononuclear cells (PBMCs) or cerebrospinal fluid (CSF) has been investigated as a biomarker for neurodegenerative disease progression 60. Elevated pERK1/2 levels correlate with disease severity in both AD and PD, though specificity remains a concern 61. Longitudinal studies suggest that pERK1/2 may serve as a progression biomarker, with levels increasing as disease advances 62. ^{5CitationPMID 21331656Open reference}3

The cell-type specificity of pERK1/2 measurements provides additional diagnostic information. Monocyte pERK1/2 reflects inflammatory status, while lymphocyte pERK1/2 may indicate adaptive immune responses 63. ^{5CitationPMID 21331656Open reference}4

Genetic Variants in MAPK Pathway

Polymorphisms in genes encoding MAPK pathway components influence susceptibility to neurodegenerative diseases. MAPK3 (ERK1) variants have been associated with altered risk for both AD and PD in genome-wide association studies 64. Functional characterization of these variants reveals altered kinase activity and substrate preference, providing mechanistic insight into their disease-modifying effects 65. ^{5CitationPMID 21331656Open reference}5

Rare variants in MAPK pathway genes identified through exome sequencing provide additional insight into pathway function in neurodegeneration. These variants often show stronger effect sizes than common GWAS hits 66. ^{5CitationPMID 21331656Open reference}6

Interaction with Other Signaling Pathways

Cross-talk with PI3K/Akt

The ERK/MAPK pathway engages in extensive cross-talk with the PI3K/Akt signaling pathway, which is also critically involved in neuronal survival 67. In neurodegenerative conditions, this cross-talk becomes dysregulated, with altered feedback loops and signal integration 68. The convergence of these pathways creates potential therapeutic targets, as simultaneous modulation may provide additive benefits 69. ^{5CitationPMID 21331656Open reference}7

Under normal conditions, Akt can phosphorylate and inhibit Raf, creating negative regulation of ERK1/2 signaling 70. In neurodegeneration, this inhibitory relationship may be disrupted, contributing to aberrant ERK1/2 activation 71. Additionally, ERK1/2 can phosphorylate and regulate Akt pathway components, creating bidirectional communication 72. ^{5CitationPMID 21331656Open reference}8

Relationship with GSK-3β

Glycogen synthase kinase-3 beta (GSK-3β) represents another key kinase that interacts with ERK1/2 in neurodegeneration. Both kinases can phosphorylate tau protein, and their synergistic activity accelerates tau pathology 73. ERK1/2 activation can increase GSK-3β activity through multiple mechanisms, creating a pathogenic feed-forward loop 74. ^{5CitationPMID 21331656Open reference}9

In Parkinson’s Disease, ERK1/2 and GSK-3β cooperatively promote alpha-synuclein phosphorylation and aggregation 75. This interaction provides a molecular basis for the observed synergy between these two pathological proteins 76. Therapeutic strategies targeting both kinases simultaneously may prove more effective than single-target approaches 77. ^{6CitationPMID 23422672Open reference}0

NF-κB Integration

The NF-κB transcription factor pathway intersects with ERK1/2 signaling in the regulation of ^{6CitationPMID 23422672Open reference}1(/mechanisms/neuroinflammation) 78. ERK1/2 can directly phosphorylate and activate NF-κB pathway components, amplifying inflammatory responses in neurodegenerative diseases 79. This integration explains the observed coordination between ERK activation and pro-inflammatory gene expression 80. ^{6CitationPMID 23422672Open reference}2

In microglia, ERK1/2-dependent NF-κB activation drives the production of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6 81. The inhibition of this axis represents a therapeutic strategy for reducing ^{6CitationPMID 23422672Open reference}3(/mechanisms/neuroinflammation) 82. However, the complex role of NF-κB in both pro-survival and pro-death pathways complicates therapeutic targeting 83. ^{6CitationPMID 23422672Open reference}4

Age-Related Changes in ERK/MAPK Signaling

Declining Neurotrophin Signaling

With aging, ERK1/2 responsiveness to neurotrophic factors declines, contributing to reduced synaptic plasticity and neuronal vulnerability 84. This decline involves multiple mechanisms including reduced receptor expression, impaired upstream signaling, and altered phosphatase activity 85. The age-related reduction in ERK1/2-mediated neuroprotective responses may explain increased susceptibility to neurodegenerative stimuli in older individuals 86. ^{6CitationPMID 23422672Open reference}5

The decline in neurotrophin-ERK signaling relates to reduced BDNF expression and TrkB receptor signaling in the aging brain. Exercise and environmental enrichment can partially counteract these age-related changes 87. ^{6CitationPMID 23422672Open reference}6

Epigenetic Regulation

ERK/MAPK signaling influences epigenetic modifications that regulate gene expression in neurodegeneration. ERK1/2 phosphorylates histone modifiers including histone acetyltransferases and methyltransferases, altering chromatin accessibility 88. In AD, dysregulated ERK1/2 signaling contributes to epigenetic alterations that further impair neuronal function 89. ^{6CitationPMID 23422672Open reference}7

DNA methylation changes associated with aging affect ERK pathway genes, creating a feedback loop between aging and pathway dysregulation 90. ^{6CitationPMID 23422672Open reference}8

Circadian Regulation of ERK/MAPK

Diurnal Rhythms

ERK1/2 phosphorylation exhibits circadian rhythms in the brain, with peak activation during the active phase 91. This rhythmicity is regulated by both clock genes and behavioral states, integrating metabolic and environmental cues 92. Disruption of circadian ERK1/2 rhythms may contribute to sleep disturbances common in neurodegenerative diseases 93. ^{6CitationPMID 23422672Open reference}9

Clock genes including BMAL1 and CLOCK directly regulate the expression of MAPK pathway components, creating a molecular link between circadian regulation and stress responses 94. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}0

Sleep Deprivation Effects

Sleep deprivation impairs ERK1/2 signaling in the brain, reducing synaptic plasticity and cognitive function 95. Given the prevalence of sleep disturbances in neurodegenerative diseases, impaired ERK1/2 signaling may represent a mechanism linking sleep dysfunction to disease progression 96. Sleep hygiene interventions may help maintain ERK1/2 signaling integrity 97. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}1

Sex Differences in ERK/MAPK Signaling

Estrogen Modulation

Estrogen modulates ERK1/2 signaling in the brain, with protective effects in female neurons 98. This modulation involves both genomic and non-genomic mechanisms, including direct activation of MAPK signaling by estrogen receptors 99. The sex-specific regulation of ERK1/2 may contribute to the sexually dimorphic incidence of neurodegenerative diseases 100. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}2

Implications for Disease

Sex differences in ERK1/2 signaling may influence disease progression and treatment response in neurodegenerative disorders. Studies suggest that estrogen-mediated enhancement of ERK1/2 signaling contributes to the protective effects of estrogen replacement therapy 101. However, the complex relationship between sex, ERK1/2 signaling, and neurodegeneration requires further investigation 102. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}3

Environmental and Lifestyle Factors

Exercise and ERK1/2

Physical exercise activates ERK1/2 signaling in the brain, mediating many of its neuroprotective effects 103. Exercise-induced ERK1/2 activation promotes neurogenesis, synaptic plasticity, and cognitive function 104. In neurodegenerative disease models, exercise provides benefits partly through ERK1/2-dependent mechanisms 105. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}4

Dietary Influences

Dietary factors modulate ERK1/2 signaling in the brain, offering potential therapeutic interventions 106. Calorie restriction, which extends lifespan and reduces neurodegeneration, influences ERK1/2 activity 107. Ketogenic diets, being explored for neurodegenerative diseases, interact with ERK1/2 signaling through multiple mechanisms 108. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}5

Future Research Directions

Spatial and Temporal Specificity

A major challenge in understanding ERK/MAPK signaling in neurodegeneration is achieving spatial and temporal specificity in studies. ERK1/2 activation patterns vary significantly between brain regions, cell types, and disease stages 109. Advanced techniques including single-cell RNA sequencing and spatial transcriptomics will help elucidate these nuances 110. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}6

Systems Biology Approaches

Integrative systems biology approaches that incorporate ERK/MAPK signaling into broader network models will improve understanding of disease mechanisms 111. Such models can identify critical network nodes for therapeutic intervention and predict off-target effects 112. ^{7Parkin and PINK1 in mitochondrial quality controlPMID 25500549Open reference}7

See Also

• Alzheimer’s disease

• Parkinson’s Disease

External Links

• PubMed

• KEGG Pathways

Pathway Diagram

The following diagram shows key molecular relationships for erk-mapk-signaling-neurodegeneration based on knowledge graph edges:

graph TD
    ERK["ERK"] -.->|"inhibits"| TTP["TTP"]
    ERK["ERK"] -->|"phosphorylates"| YTHDF2["YTHDF2"]
    SRC["SRC"] -->|"activates"| ERK["ERK"]
    FLAVONOIDS["FLAVONOIDS"] -->|"regulates"| ERK["ERK"]
    NRBP1["NRBP1"] -->|"participates in"| ERK["ERK"]
    PIEZO1["PIEZO1"] -->|"activates"| ERK["ERK"]
    EGFR["EGFR"] -->|"activates"| ERK["ERK"]
    GPR146["GPR146"] -->|"activates"| ERK["ERK"]
    ERK["ERK"] -->|"activates"| CREB["CREB"]
    AMBRA1["AMBRA1"] -->|"regulates"| ERK["ERK"]
    R_ketamine["R-ketamine"] -->|"activates"| ERK["ERK"]
    n6_OHDA["6-OHDA"] -->|"associated with"| ERK["ERK"]
    style ERK fill:#8d4900,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0
    style TTP fill:#1b5e20,stroke:#333,color:#e0e0e0
    style YTHDF2 fill:#1b5e20,stroke:#333,color:#e0e0e0
    style SRC fill:#1b5e20,stroke:#333,color:#e0e0e0
    style FLAVONOIDS fill:#006494,stroke:#333,color:#e0e0e0
    style NRBP1 fill:#006494,stroke:#333,color:#e0e0e0
    style PIEZO1 fill:#006494,stroke:#333,color:#e0e0e0
    style EGFR fill:#006494,stroke:#333,color:#e0e0e0
    style GPR146 fill:#1b5e20,stroke:#333,color:#e0e0e0
    style CREB fill:#1b5e20,stroke:#333,color:#e0e0e0
    style AMBRA1 fill:#1b5e20,stroke:#333,color:#e0e0e0
    style R_ketamine fill:#5d4400,stroke:#333,color:#e0e0e0
    style n6_OHDA fill:#006494,stroke:#333,color:#e0e0e0

Pathway Diagram

The following diagram shows the key molecular relationships involving erk-mapk-signaling-neurodegeneration discovered through SciDEX knowledge graph analysis:

graph TD
    ERK1["ERK1"] -->|"activates"| ERK["ERK"]
    INFLAMMATION["INFLAMMATION"] -->|"activates"| ERK["ERK"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| ERK["ERK"]
    BAX["BAX"] -->|"activates"| ERK["ERK"]
    MEK["MEK"] -->|"phosphorylates"| ERK["ERK"]
    trametinib["trametinib"] -.->|"inhibits"| ERK["ERK"]
    NUPR1["NUPR1"] -.->|"inhibits"| ERK["ERK"]
    MEK["MEK"] -->|"activates"| ERK["ERK"]
    SPP1["SPP1"] -->|"activates"| ERK["ERK"]
    RB5["RB5"] -->|"activates"| ERK["ERK"]
    AKT["AKT"] -.->|"inhibits"| ERK["ERK"]
    AMYLOID["AMYLOID"] -->|"associated with"| ERK["ERK"]
    NLGN3["NLGN3"] -->|"activates"| ERK["ERK"]
    IGF1R["IGF1R"] -->|"activates"| ERK["ERK"]
    MADD["MADD"] -->|"upstream of"| ERK["ERK"]
    style ERK1 fill:#ce93d8,stroke:#333,color:#000
    style ERK fill:#4fc3f7,stroke:#333,color:#000
    style INFLAMMATION fill:#ce93d8,stroke:#333,color:#000
    style ALZHEIMER_S_DISEASE fill:#ef5350,stroke:#333,color:#000
    style BAX fill:#ce93d8,stroke:#333,color:#000
    style MEK fill:#4fc3f7,stroke:#333,color:#000
    style trametinib fill:#ff8a65,stroke:#333,color:#000
    style NUPR1 fill:#ce93d8,stroke:#333,color:#000
    style SPP1 fill:#4fc3f7,stroke:#333,color:#000
    style RB5 fill:#ff8a65,stroke:#333,color:#000
    style AKT fill:#ce93d8,stroke:#333,color:#000
    style AMYLOID fill:#4fc3f7,stroke:#333,color:#000
    style NLGN3 fill:#4fc3f7,stroke:#333,color:#000
    style IGF1R fill:#4fc3f7,stroke:#333,color:#000
    style MADD fill:#4fc3f7,stroke:#333,color:#000